ECNP 2025 38th ECNP Congress Poster – LB-102 for acute schizophrenia in adults: efficacy and safety from a large phase 2 clinical trial
ECNP 2025 38th ECNP Congress Poster – LB-102 for acute schizophrenia in adults: Results from the phase 2 clinical trial (NOVA1) with a focus on Negative Symptoms
ECNP 2025 38th ECNP Congress Poster – LB-102 for cognitive impairment in schizophrenia: exploratory post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study
ASCP 2025 American Society of Clinical Psychopharmacology Poster – “Oral, Once-Daily LB-102: Recent Positive Results From a Phase 2 Study in Patients With Acute Schizophrenia”
SIRS 2025 Schizophrenia International Research Society Poster – “LB-102 for Acute Schizophrenia in Adults: Efficacy and Safety From a Large Phase 2 Clinical Trial”
Nature Neuropsychopharmacology October 2024 Nature Neuropsychopharmacology: PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement
ASCP 2024 American Society of Clinical Psychopharmacology Poster – “LB-102, a novel benzamide for the treatment of schizophrenia: safety and dopamine receptor occupancy data from two clinical studies”
Springer Nature Psychopharmacology July 2022 A randomized, double‑blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB‑102
ACNP 2021 American College of Neuropsychopharmacology Poster – “PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor engagement”
ECNP 2021 European College of Neuropsychopharmacology Poster – “LB-102 displays superior dopamine receptor occupancy compared to amisulpride in mouse and human PET studies”
ECNP 2020 European College of Neuropsychopharmacology Poster – “Safety, pharmacokinetics, and pharmacodynamics of LB-102, a selective D2/5-HT7 antagonist, in healthy volunteers”
ECNP 2019 European College of Neuropsychopharmacology Poster – “Building a translational bridge from animals to man for clinical candidate LB-102, a next-generation benzamide antipsychotic”
ACS Omega 2019 Peer-reviewed Publication – Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5‑HT7
ECNP 2018 European College of Neuropsychopharmacology Poster – “LB-102, Potential Schizophrenia Treatment, Displays Polypharmacology as a Racemate—S Enantiomer Binds D2 Receptors and R Binds 5-HT7Receptor”
SOBP May 2018 Society of Biological Psychiatry Poster – “Establishing a PK-PD-E Relationship for Clinical Candidate LB-102, a Next-Generation Benzamide Antipsychotic”
ECNP Sept 2017 European College of Neuropsychopharmacology Poster – “Pre-clinical Evaluation of Two Novel Benzamides LB-102 and 103 for the Treatment of Schizophrenia”
